糖尿病合并卒中相关性肺炎患者支气管镜辅助吸痰的疗效

呼玮, 陈谨

武警医学 ›› 2020, Vol. 31 ›› Issue (8) : 665-668.

PDF(683 KB)
PDF(683 KB)
武警医学 ›› 2020, Vol. 31 ›› Issue (8) : 665-668.
论著

糖尿病合并卒中相关性肺炎患者支气管镜辅助吸痰的疗效

  • 呼玮, 陈谨
作者信息 +

Efficacy of bronchoscopic sputum aspiration in patients with diabetes mellitus complicated with stroke-associated pneumonia

  • HU Wei, CHEN Jin
Author information +
文章历史 +

摘要

目的 观察支气管镜吸痰辅助治疗糖尿病合并卒中相关性肺炎(stroke-associated pneumonia,SAP)的效果。方法 选取2017-07至2018-12首都医科大学附属复兴医院住院治疗的86例糖尿病合并SAP患者,其中常规吸痰管吸痰(常规组)66例,支气管镜吸痰(干预组)20例。比较两组临床疗效,痰培养阳性率,抗菌药物使用时间、强度,住院时间、花费及不良反应发生情况。用于评估支气管镜吸痰辅助治疗在糖尿病合并SAP中的效果。结果 在治疗过程中,干预组在基础治疗上给予患者每周1~2次支气管镜吸痰治疗,每人平均行气管镜(1.6±0.6)次,每次平均间隔(7.8±2.3)d。干预组临床总有效率(100%)高于常规组(74.2%),差异有统计学意义(χ2=4.899,P=0.027);干预组痰培养阳性率(70.0%)高于常规组(27.3%),差异有统计学意义(χ2=11.993,P=0.001);干预组抗菌药物使用时间[(8.3±1.9)d]少于常规组[(11.0±8.0)d],干预组抗菌药物使用强度[(10.2±3.2) DDD]低于常规组[(13.5±8.0)DDD],干预组平均住院时间[(11.7±2.5)d]短于常规组[(14.0±11.0)d],干预组平均住院花费[(15 956.2±4472.6)元]少于常规组[(19 673.5±15 041.5)元],以上差异均有统计学意义(P<0.05)。两组患者治疗过程中均未出现咯血,严重心律失常等不良反应。结论 支气管镜吸痰辅助治疗糖尿病合并SAP临床疗效好,痰培养阳性率高,可以减少抗生素使用时间及强度,无严重不良反应。

Abstract

Objective To observe the therapeutic effect of bronchoscopic sputum aspiration against diabetes mellitus complicated with stroke-associated pneumonia.Methods Eighty-six patients with diabetes mellitus complicated with stroke-associated pneumonia were selected from Fuxing Hospital between July 2017 and December 2018. Among these patients, 66 were treated with the sputum suction tube (routine group) and the rest with sputum suction aided by a bronchoscope (intervention group). The clinical efficacy, sputum culture positive rate, duration and intensity of antimicrobial use, length of hospital stay, cost and adverse reactions were observed and compared between the two groups in order to evaluate the effect of bronchoscopic sputum suction in diabetes mellitus with SAP.Results In the course of treatment, the intervention group was treated with bronchoscopic sputum suction once or twice a week in addition to basic treatment, and each patient was treated with bronchoscopy (1.6±0.6) times, at an average interval of (7.8±2.3) days. The total effective rate (100%) of the intervention group was higher than that of the conventional group (74.2%) (χ2=4.899, P=0.027). The positive rate of sputum culture (70.0%) of the intervention group was higher than that of the conventional group (27.3%) (χ2=11.993, P=0.001). Antibiotics were used for a shorter period of time in the intervention group (8.3±1.9 days) than in the conventional group (11.0±8.0 days) (Z=-2.715, P=0.007). The intensity of antibacterials was lower in the intervention group (10.2±3.2)ddd than in the control group (13.5±8.0) ddd (t=-3.309, P=0.002). The average length of hospital stay in the intervention group (11.7±2.5 days) was shorter than in the conventional group (14.0±11.0) days (Z=-2.421, P= 0.015). The average cost of hospitalization in the intervention group (15956.2±4472.6)yuan was lower than in the conventional group (19673.5±15041.5) yuan (Z=-2.474, P=0.013). There were no adverse reactions such as hemoptysis or serious arrhythmia in either group.Conclusions Bronchoscopic sputum aspiration for diabetes mellitus complicated with stroke-associated pneumonia has good clinical efficacy and high positive rate of sputum culture. It can reduce the duration and intensity of antibiotic use, shorten the hospital stay of patients, reduce hospitalization costs, and cause no serious adverse reactions.

关键词

卒中相关性肺炎 / 糖尿病 / 支气管镜吸痰

Key words

stroke-associated pneumonia / diabetes / bronchoscopic sputum aspiration

引用本文

导出引用
呼玮, 陈谨. 糖尿病合并卒中相关性肺炎患者支气管镜辅助吸痰的疗效[J]. 武警医学. 2020, 31(8): 665-668
HU Wei, CHEN Jin. Efficacy of bronchoscopic sputum aspiration in patients with diabetes mellitus complicated with stroke-associated pneumonia[J]. Medical Journal of the Chinese People Armed Police Forces. 2020, 31(8): 665-668
中图分类号: R587.1    R563.1   

参考文献

[1] 杜函洋,徐 玢,杨铁城, 等.肺泡灌洗辅助治疗卒中相关性肺炎的临床研究[J].中国临床医生杂志,2018,46(12):1422-1425.
[2] 赵 洋,刘 强,张 毅, 等.卒中相关性肺炎的相关危险因素及预测因子分析[J].中国医药导刊,2017,19(11):1117-1120.
[3] 潘希丁,周俊山.卒中相关性肺炎诊疗进展[J].医学综述,2018,24(3):538-542.
[4] 张丽艳,崔 跃.盐酸氨溴索联合头孢哌酮钠舒巴坦钠治疗老年糖尿病合并肺炎的疗效观察[J].中国医院用药评价与分析,2017,17(11):1506-1508.
[5] 翟文亮,刘利欣,李俊芬, 等.合并糖尿病的老年肺炎住院患者营养风险评估及短期预后[J].医学研究杂志,2018,47(8):129-132,136.
[6] 翟文亮,刘利欣,李俊芬, 等.合并糖尿病的老年社区获得性肺炎患者营养风险评估及短期预后[J].中国医刊,2018,53(3):306-310.
[7] 熊小芹,罗光涛,石亚军.老年糖尿病患者合并社区获得性肺炎临床特点分析[J].川北医学院学报,2015,30(2):240-242,252.
[8] 赵 航,赵洪文.糖尿病患者合并社区获得性肺炎的临床特点及预后分析[J].国际呼吸杂志,2017,37(13):1013-1017.
[9] 王莉莉.盐酸氨溴素注射液联合头孢哌酮钠舒巴坦治疗糖尿病合并肺炎患者临床症状及对肺功能的影响[J].昆明医科大学学报,2019,40(5):117-121.
[10] 冯少丹,江 勇,郭平清, 等.氨溴索治疗老年糖尿病合并重症肺炎的疗效分析[J].中国老年学杂志,2015,35(17):4856-4857.
[11] 陈茂林,杨青松.重症肺炎合并糖尿病患者预后影响因素分析[J].实用医院临床杂志,2018,15(6):138-141.
[12] 李辉明,谢建军.2型糖尿病合并医院获得性肺炎病原学特点及药物敏感试验分析[J].临床肺科杂志,2016,21(7):1242-1245.
[13] 高志飞,崔 巍,雷金娥, 等.2型糖尿病患者合并肺炎克雷伯菌败血症的临床分析[J].西安交通大学学报(医学版),2016,37(6):835-840.
[14] 朱琳玲.吸入用乙酰半胱氨酸辅助口服莫西沙星对门诊老年糖尿病合并社区获得性肺炎患者症状评分、炎性细胞因子及免疫功能的影响[J].湖南师范大学学报(医学版),2017,14(5):83-86.
[15] 贾晓利,李会东.老年2型糖尿病合并社区获得性肺炎的临床特征[J].河北医药,2016,38(5):743-744.
[16] 韩 瑛,张 丽.莫西沙星与左氧氟沙星对2型糖尿病合并社区获得性肺炎血清炎症因子的研究[J].山西医药杂志,2018,47(23):2863-2865.
[17] 向 茜,熊 昕.卒中相关性肺炎诊治进展[J].中西医结合心脑血管病杂志,2015,13(7):908-910.
[18] 单 凯,贾东梅,郭 伟.卒中相关性肺炎的诊断—卒中并发肺炎研究组专家共识[J].中华急诊医学杂志,2015,24(12):1346-1348.
[19] 卒中相关性肺炎诊治中国专家共识组.卒中相关性肺炎诊治中国专家共识[J].中华内科杂志,2010,49(12):1075-1078.
[20] 应令雯,周 健.2017年ADA糖尿病医学诊疗标准解读[J].中国循环杂志,2017,32(z2):154-161.

PDF(683 KB)

Accesses

Citation

Detail

段落导航
相关文章

/